Stem cell pioneer lures big pharma – The Australian Financial Review
The Australian Financial Review |
Stem cell pioneer lures big pharma
The Australian Financial Review It has made a down-payment to get its hands on the intellectual property of a leader in stem cell research. The biotech game is extremely complex and risky but the rewards can be enormous. For example, a recent report on Celgene by analysts at … Shares in this Australian stem cell company are going nuts on an investment … Mesoblast Shoots To A 4-Year High On News Of Celgene Corporation Buying … Mesoblast takes partnership with Celgene, shares rise 24pc |
